AXA Investment Managers’s NewAmsterdam Pharma NAMS Stock Holding History

AXA Investment Managers’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$5.6M	Buy	+196,782	New	+$4.72M	0.02%	542

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AXA Investment Managers's NAMS Position: Q3 2025 in Review

AXA Investment Managers opened a new position in NewAmsterdam Pharma (NAMS) in Q3 2025: 196,782 shares worth $5.6M. The stake represents 0.02% of the portfolio and ranks #542 among its holdings.

137 funds tracked by Wall St. Rank hold NAMS as of Q3 2025.

AXA Investment Managers held 196,782 shares of NewAmsterdam Pharma worth $5.6M as of Q3 2025.
NewAmsterdam Pharma was a new AXA Investment Managers position in Q3 2025.
NewAmsterdam Pharma made up 0.02% of AXA Investment Managers's portfolio in Q3 2025, its #542 holding.
137 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.